UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Sep

    26

    UCB Achieves Two Awards Recognizing our Sustainability Efforts for the Atlanta Warehouse Expansion

    Aug

    16

    How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

    As students and parents prepare for a new school year, there can be a lot of stress  – from meeting new teachers and preparing for classes, to financial assistance and making new friends. For people living with epilepsy and their caregivers, the stress and worry surrounding back-to-school preparation is compounded.

    Jun

    13

    UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

    Jun

    06

    UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

    Today, UCB was pleased to host Her Royal Highness Princess Astrid of Belgium (HRH), Belgian dignitaries, and Belgian business leaders to visit our U.S. headquarters in Atlanta, Georgia.

    Jun

    01

    Life with MG & What I Wish For Everyone Who is Diagnosed

    May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    Feb

    22

    Partnering for Greater Impact with Microsoft in R&D

    At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

    Oct

    22

    UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

    UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21.